Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial - PubMed (original) (raw)

Randomized Controlled Trial

Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial

Laura A Young et al. JAMA Intern Med. 2017.

Abstract

Importance: The value of self-monitoring of blood glucose (SMBG) levels in patients with non-insulin-treated type 2 diabetes has been debated.

Objective: To compare 3 approaches of SMBG for effects on hemoglobin A1c levels and health-related quality of life (HRQOL) among people with non-insulin-treated type 2 diabetes in primary care practice.

Design, setting, and participants: The Monitor Trial study was a pragmatic, open-label randomized trial conducted in 15 primary care practices in central North Carolina. Participants were randomized between January 2014 and July 2015. Eligible patients with type 2 non-insulin-treated diabetes were: older than 30 years, established with a primary care physician at a participating practice, had glycemic control (hemoglobin A1c) levels higher than 6.5% but lower than 9.5% within the 6 months preceding screening, as obtained from the electronic medical record, and willing to comply with the results of random assignment into a study group. Of the 1032 assessed for eligibility, 450 were randomized.

Interventions: No SMBG, once-daily SMBG, and once-daily SMBG with enhanced patient feedback including automatic tailored messages delivered via the meter.

Main outcomes and measures: Coprimary outcomes included hemoglobin A1c levels and HRQOL at 52 weeks.

Results: A total of 450 patients were randomized and 418 (92.9%) completed the final visit. There were no significant differences in hemoglobin A1c levels across all 3 groups (P = .74; estimated adjusted mean hemoglobin A1c difference, SMBG with messaging vs no SMBG, -0.09%; 95% CI, -0.31% to 0.14%; SMBG vs no SMBG, -0.05%; 95% CI, -0.27% to 0.17%). There were also no significant differences found in HRQOL. There were no notable differences in key adverse events including hypoglycemia frequency, health care utilization, or insulin initiation.

Conclusions and relevance: In patients with non-insulin-treated type 2 diabetes, we observed no clinically or statistically significant differences at 1 year in glycemic control or HRQOL between patients who performed SMBG compared with those who did not perform SMBG. The addition of this type of tailored feedback provided through messaging via a meter did not provide any advantage in glycemic control.

Trial registration: clinicaltrials.gov Identifier: NCT02033499.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Young reports grants from Eli Lilly, grants from Bristol-Myers Squibb, grants and other from GI Dynamics, grants from PhaseBio, grants from Medtronic Minimed, grants from Sanofi, grants from Tolerex, grants from Halozyme, grants from Johnson & Johnson, grants from Andromeda, grants from Boehringer-Ingelheim, grants from GlaxoSmithKline, grants from Intarcia Therapeutics, grants from Lexicon, grants from Scion NeuroStim, grants from Orexigen, grants from Takeda, grants from Theracos, grants from Novo Nordisk, other from Dexcom, outside the submitted work; she is a member of the planning committee for Taking Control of Your Diabetes; and UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. Dr Buse reports grants, nonfinancial support, and other from Eli Lilly, grants, nonfinancial support, and other from Bristol-Myers Squibb, grants, nonfinancial support, and other from GI Dynamics, nonfinancial support and other from Elcylex, grants, nonfinancial support, and other from Merck, nonfinancial support and other from Metavention, nonfinancial support and other from vTv Pharma, grants, personal fees, nonfinancial support, and other from PhaseBio, grants, nonfinancial support, and other from AstraZeneca, nonfinancial support and other from Dance Biopharm, nonfinancial support and other from Quest, grants from Medtronic Minimed, grants, nonfinancial support, and other from Sanofi, grants from Tolerex, grants from Osiris, grants from Halozyme, grants from Johnson & Johnson, grants from Andromeda, grants from Boehringer-Ingelheim, grants from GlaxoSmithKline, grants from Astellas, grants from MacroGenics, grants from Intarcia Therapeutics, grants, nonfinancial support, and other from Lexicon, grants from Scion NeuroStim, grants, nonfinancial support, and other from Orexigen, grants, nonfinancial support, and other from Takeda, nonfinancial support and other from Adocia, grants, nonfinancial support, and other from F. Hoffman LaRoche, grants from Theracos, grants, nonfinancial support, and other from Novo Nordisk outside the submitted work; and he is or has been a member of a variety of nonprofit boards: American Diabetes Association, DiabetesSisters, Taking Control of Your Diabetes, AstraZeneca Healthcare Foundation, Bristol-Myers Squib Together on Diabetes Foundation, the National Diabetes Education Program; and UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. Dr Donahue reports UNC has licensed its interest in copyright works to Telcare of a glucose messaging and treatment algorithm for the purposes of commercialization. No other disclosures are reported.

Figures

Figure 1.

Figure 1.. The Monitor Trial CONSORT Flow Diagram

SMBG indicates self-monitoring of blood glucose.

Figure 2.

Figure 2.. Mean Hemoglobin A1c by Study Arm Over Time and Daily Proportions of Patients Testing in the SMBG Groups

A, Model-estimated mean hemoglobin A1c values obtained by fitting a quadratic polynomial regression with linear mixed models using all observed hemoglobin A1c values, including those at interim visits, but excluding any following insulin use. The model included 1875 total hemoglobin A1c measurements from 450 patients; only 10 patients contributed no interim hemoglobin A1c measurements and the median number was 4. The intervals represent pointwise 95% CIs for each group, and the P values compare the average of the SMBG groups with the no SMBG group. B, Daily proportions of patients in the SMBG groups uploading a result with the meter on each study day. Lines represent locally weighted smoothing using local quadratic polynomials across the observed proportions. SMBG Indicates self-monitoring of blood glucose.

Comment in

Similar articles

Cited by

References

    1. American Diabetes Association 5. Glycemic targets. Diabetes Care. 2016;39(suppl 1):S39-S46. - PubMed
    1. Allemann S, Houriet C, Diem P, Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Curr Med Res Opin. 2009;25(12):2903-2913. - PubMed
    1. Clar C, Barnard K, Cummins E, Royle P, Waugh N. Aberdeen Health Technology Assessment Group . Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess. 2010;14(12):1-140. - PubMed
    1. Farmer AJ, Perera R, Ward A, et al. . Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ. 2012;344:e486-e486. - PubMed
    1. Malanda UL, Welschen LM, Riphagen II, Dekker JM, Nijpels G, Bot SD Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database of Systematic Reviews. http://onlinelibrary.wiley.com.libproxy.lib.unc.edu/doi/10.1002/14651858.... Login required. Accessed April 9, 2017. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources